SARS-CoV-2 3CLpro-IN-5
Product Specifications
UNSPSC Description
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19)[1].
Target Antigen
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-3clpro-in-5.html
Solubility
10 mM in DMSO
Smiles
FC1=CC=CC2=C1C=C(C(N[C@H](C(NN(C([C@@](F)([H])Cl)=O)C[C@H]3C(NCC3)=O)=O)CC(C)C)=O)N2
Molecular Weight
497.92
References & Citations
[1]Yuya Hirose, et al. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. J Med Chem
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-151535/SARS-CoV-2-3CLpro-IN-5-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-151535/
Clinical Information
No Development Reported
CAS Number
2913186-57-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CSB-CF808540HU-01 20 µg
Recombinant Human Cyclic nucleotide-gated cation channel alpha-4 (CNGA4)
Ask
View Details CSB-CF808540HU-02 100 µg
Recombinant Human Cyclic nucleotide-gated cation channel alpha-4 (CNGA4)
Ask
View Details